Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorolanib + Toripalimab as First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma
ChiCTR2500111737Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vorolanib and toripalimab in renal cell carcinoma (RCC), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Progression-Free Survival. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
vorolanibtoripalimab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ChiCTR2500111737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111737.